Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
CNS Drugs
Erschienen in: CNS Drugs 11/2001

01.11.2001 | Therapy in Practice

Multiple System Atrophy

Pathophysiology and Management

verfasst von: Dr Gregor Karl Wenning, Stefan Braune

Erschienen in: CNS Drugs | Ausgabe 11/2001

Einloggen, um Zugang zu erhalten

Abstract

Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder that usually manifests when an individual is in his/her early fifties and progresses relentlessly with a mean survival of 9 years. Clinically, MSA is dominated by autonomic/urogenital failure which may be associated with either parkinsonism (MSA-P subtype) in 80% of cases or with cerebellar ataxia (MSA-C subtype) in 20% of cases. Pathologically, MSA is characterised by a neuronal multisystem degeneration and abnormal glial cytoplasmic inclusions containing α-synuclein aggregates.
Autonomie and urogenital features of MSA should be identified early on because they can be treated effectively in many instances. In contrast, pharmacological treatment of motor features is often disappointing, except for a minority of patients with MSA-P who derive transient benefit from levodopa treatment.
In the future, neurotransplantation may extend or improve the treatment response in MSA-P, but further preclinical evidence is required prior to clinical application. Neuroprotection strategies may slow down disease progression in MSA and the results of the first double-blind trial of riluzole (an inhibitor of glutamate release) in patients with MSA will be available in 2004.
Literatur
1.
Bower JH, Maraganore DM, McDonnell SK, et al. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 1997; 49: 1284–8PubMedCrossRef
2.
Schrag A, Ben-Shlomo Y, Quinn NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet 1999; 354: 1771–5PubMedCrossRef
3.
Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999; 163: 94–8PubMedCrossRef
4.
Wenning GK, Jager R, Kendall B, et al. Is cranial computerized tomography useful in the diagnosis of multiple system atrophy? Mov Disord 1994; 9: 333–6PubMedCrossRef
5.
Quinn N. Multiple system atrophy — the nature of the beast. J Neurol Neurosurg Psychiatry 1989 Jun; Suppl.: 78–89
6.
Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, editors. Movement disorders III. London: Butterworth-Heinemann, 1994: 262–81
7.
Litvan I, Booth V, Wenning GK, et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm 1998; 105: 217–27PubMedCrossRef
8.
Dickson DW, Liu W, Hardy J, et al. Widespread alterations of alpha-synuclein in multiple system atrophy. Am J Pathol 1999; 155: 1241–51PubMedCrossRef
9.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994
10.
Terao S, Sobue G, Hashizume Y, et al. Disease-specific patterns of neuronal loss in the spinal ventral horn in amyotrophic lateral sclerosis, multiple system atrophy and X-linked recessive bulbospinal neuronopathy, with special reference to the loss of small neurons in the intermediate zone. J Neurol 1994; 241: 196–203PubMedCrossRef
11.
Daniel SE. The neuropathology and neurochemistry of multiple system atrophy. In: Bannister R, Mathias CJ, editors. Autonomic failure. 3rd ed. Oxford: Oxford Medical Publications, 1992: 564–87
12.
Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999; 14: 947–50PubMedCrossRef
13.
Papp MI, Lantos PL. Accumulation of tubular structures in oligodendroglial and neuronal cells as the basic alteration in multiple system atrophy. J Neurol Sci 1992; 107: 172–82PubMedCrossRef
14.
Lantos PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol 1998; 57: 1099–111PubMedCrossRef
15.
Papp MI, Lantos PL. The distribution of oligodendroglial inclusions in multiple system atrophy and its relevance to clinical symptomatology. Brain 1994; 117: 235–43PubMedCrossRef
16.
Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy Drager syndrome). J Neurol Sci 1989; 94: 79–100PubMedCrossRef
17.
Cairns NJ, Atkinson PF, Hanger DP, et al. Tau protein in the glial cytoplasmic inclusions of multiple system atrophy can be distinguished from abnormal tau in Alzheimer’s disease. Neurosci Lett 1997; 230: 49–52PubMedCrossRef
18.
Goedert M, Spillantini MG. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry 1998; 3: 462–5PubMedCrossRef
19.
Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40PubMedCrossRef
20.
Wakabayashi K, Yoshimoto M, Tsuji S, et al. α-Synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 1998; 249: 180–2PubMedCrossRef
21.
Arima K, Ueda K, Sunohara N, et al. NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol (Berl) 1998; 96: 439–44CrossRef
22.
Tu P, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann Neurol 1998; 44: 415–22PubMedCrossRef
23.
Clayton DF, George JM. Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res 1999; 58: 120–9PubMedCrossRef
24.
Farrer M, Wavrant-De Vrieze F, Crook R, et al. Low frequency of alpha-synuclein mutations in familial Parkinson’s disease. Ann Neurol 1998; 43: 394–7PubMedCrossRef
25.
Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet 1998; 18: 106–8PubMedCrossRef
26.
Ozawa T, Takano H, Onodera O, et al. No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy. Neurosci Lett 1999; 270: 110–2PubMedCrossRef
27.
Wenning GK, Wagner S, Daniel S, et al. Multiple system atrophy: sporadic or familial? Lancet 1993; 342: 681CrossRef
28.
Bandmann O, Sweeney MG, Daniel SE, et al. Multiple-system atrophy is genetically distinct from identified inherited causes of spinocerebellar degeneration. Neurology 1997; 496: 1598–604CrossRef
29.
Nicholl DJ, Bennett P, Hiller L, et al. A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism. Neurology 1999; 53: 1415–21
30.
Klockgether T, Burk K, Wullner U, et al. Risk factors for idiopathic cerebellar ataxia of late onset. J Neurol Sci 1998; 160: 171–4PubMedCrossRef
31.
Vanacore N, Bonifati V, Fabbrini G, et al. Smoking habits in multiple system atrophy and progressive supranuclear palsy. European Study Group on Atypical Parkinsonisms. Neurology 2000; 54: 114–9
32.
Matthews MR. Autonomic ganglia in multiple system atrophy and pure autonomic failure. In: Bannister R, Mathias CJ, editors. Autonomic failure. 3rd ed. Oxford: Oxford Medical Publications, 1992: 593–621
33.
Polinsky RJ, Brown RT, Lee GK, et al. Beta-endorphin, ACTH, and catecholamine responses in chronic autonomic failure. Ann Neurol 1987; 21(6): 573–7PubMedCrossRef
34.
Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson’s disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997; 349(9069): 1877–81PubMedCrossRef
35.
Kaufmann H, Oribe E, Miller M, et al. Hypotension induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42 (3 Pt 1): 590–3PubMedCrossRef
36.
Ziegler M, Lake C, Kopin I. The sympathetic nervous system defect in primary orthostatic hypotension. N Engl J Med 1977; 296: 293–7PubMedCrossRef
37.
Polinsky RJ, Kopin IJ, Ebert MH, et al. Pharmacologic distinction of different orthostatic hypotension syndromes. Neurology 1981; 31(1): 1–7PubMedCrossRef
38.
Braune S, Reinhardt M, Schnitzer R, et al. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999; 53(5): 1020–5PubMedCrossRef
39.
Orimo S, Ozawa E, Nakade S, et al. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999; 67(2): 189–94PubMedCrossRef
40.
Takatsu H, Nagashima K, Murase M, et al. Differentiating Parkinson disease from multiple-system atrophy by measuring cardiac iodine-123 metaiodobenzylguanidine accumulation. JAMA 2000; 284(1): 44–5PubMedCrossRef
41.
Taki J, Nakajima K, Hwang EH, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med 2000; 27(5): 566–73PubMedCrossRef
42.
Baser SM, Meer J, Polinsky RJ, et al. Sudomotor function in autonomic failure. Neurology 1991; 41(10): 1564–6PubMedCrossRef
43.
Cohen J, Low P, Fealey R, et al. Somatic and autonomic function in progressive autonomic failure and multiple system atrophy. Ann Neurol 1987; 22: 692–9PubMedCrossRef
44.
Sandroni P, Ahlskog JE, Fealey RD, et al. Autonomic involvement in extrapyramidal and cerebellar disorders. Clin Auton Res 1991; 1(2): 147–55PubMedCrossRef
45.
Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991; 114: 2283–301PubMedCrossRef
46.
Kume A, Takahashi A, Hashizume Y. Neuronal cell loss of the striatonigral system in multiple system atrophy. J Neurol Sci 1993; 177: 33–40CrossRef
47.
Tison F, Wenning GK, Daniel SE, et al. The pathophysiology of parkinsonism in multiple system atrophy. Eur J Neurol 1995; 2: 435–44CrossRef
48.
Wenning GK, Ben-Shlomo Y, Magalhaes M, et al. Clinical features and natural history of multiple system atrophy: an analysis of 100 patients. Brain 1994; 117: 835–45PubMedCrossRef
49.
Quik M, Spokes EG, Mackay AV, et al. Alterations in [3H]-spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson’s disease. J Neurol Sci 1979 Nov; 43(3): 429–37PubMedCrossRef
50.
Cortes R, Camps M, Gueye B, et al. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 1989 Mar 27; 483(1): 30–8PubMedCrossRef
51.
Shinotoh H, Aotsuka A, Inoue O, et al. Imaging of dopamine D1 and D2 receptors by a high resolution positron emission tomography. Adv Exp Med Biol 1991; 287: 249–53PubMedCrossRef
52.
Shinotoh H, Inoue O, Hirayama K, et al. Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993 May; 56(5): 467–72PubMedCrossRef
53.
Brooks DJ, Ibanez V, Sawle GV, et al. Striatal D2 receptor status in patients with Parkinson’s disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 84–192CrossRef
54.
Churchyard A, Donnan GA, Hughes A, et al. Dopa resistance in multiple-system atrophy: loss of postsynaptic D2 receptors. Ann Neurol 1993 Aug; 34(2): 219–26PubMedCrossRef
55.
Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration. Ann Neurol 1989; 26: 766–70PubMedCrossRef
56.
Goto S, Hirano A, Rojas-Corona RR. Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neurodegenerative disorders. Acta Neuropathol (Berl) 1989; 78: 543–50CrossRef
57.
Goto S, Hirano A, Matsumoto S. Met-enkephalin immunoreactivity in the basal ganglia in Parkinson’s disease and striatonigral degeneration. Neurology 1990 Jul; 40(7): 1051–6PubMedCrossRef
58.
Goto S, Matsumoto S, Ushio Y, et al. Subregional loss of putaminal efferents to the basal ganglia output nuclei may cause parkinsonism in striatonigral degeneration. Neurology 1996 Oct; 47(4): 1032–6PubMedCrossRef
59.
Schelosky L, Hierholzer J, Wissel J, et al. Correlation of clinical response in apomorphine test with D-2 receptor status as demonstrated by 123-IIBZM-SPECT. Mov Disord 1993; 8: 453–8PubMedCrossRef
60.
van Royen E, Verhoeff NF, Speelman JD, et al. Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography. Arch Neurol 1993 May; 50(5): 513–6
61.
Ito H, Kusaka H, Matsumoto S, et al. Striatal efferent involvement and its correlation to levodopa efficacy in patients with multiple system atrophy. Neurology 1996; 47: 1291–9PubMedCrossRef
62.
Parati EA, Fetoni V, Geminiani GC, et al. Response to L-dopa in multiple system atrophy. Clin Neuropharmacol 1993; 16: 139–44PubMedCrossRef
63.
Rajput AH, Rozdilsky B, Rajput A, et al. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol 1990 Dec; 13(6): 553–8PubMedCrossRef
64.
Sawle GV, Playford ED, Brooks DJ, et al. Asymmetrical presynaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Diagnostic implications of the D2 receptor status. Brain 1993 Aug; 116 (Pt 4): 853–67PubMedCrossRef
65.
Burn DJ, Rinne JO, Quinn NP, et al. Striatal opioid receptor binding in Parkinson’s disease, striatonigral degeneration and Steele-Richardson-Olszewski syndrome, a [11C] diprenorphine PET study. Brain 1995; 118: 951–8PubMedCrossRef
66.
Abele M, Schulz JB, Burk K, et al. Evoked potentials in multiple system atrophy (MSA). Acta Neurol Scand 2000; 101(2): 111–5PubMedCrossRef
67.
Kodama Y, Ieda T, Hirayama M, et al. Auditory brainstem responses in patients with autonomic failure with Parkinson’s disease and multiple system atrophy. J Auton Nerv Syst 1999; 77(2–3): 184–9PubMedCrossRef
68.
Delalande I, Hache JC, Forzy G, et al. Do visual-evoked potentials and spatiotemporal contrast sensitivity help to distinguish idiopathic Parkinson’s disease and multiple system atrophy? Mov Disord 1998; 13(3): 446–52PubMedCrossRef
69.
Abbruzzese G, Marchese R, Trompetto C. Sensory and motor evoked potentials in multiple system atrophy: a comparative study with Parkinson’s disease. Mov Disord 1997; 12(3): 315–21PubMedCrossRef
70.
Kofler M, Muller J, Wenning GK, et al. The auditory startle reaction in parkinsonian disorders. Mov Disord 2001; 16(1): 62–71PubMedCrossRef
71.
Pramstaller PP, Wenning GK, Smith SJ, et al. Nerve conduction studies, skeletal muscle EMG, and sphincter EMG in multiple system atrophy. J Neurol Neurosurg Psychiatry 1995; 58(5): 618–21PubMedCrossRef
72.
Ravits J, Hallett M, Nilsson J, et al. Electrophysiological tests of autonomic function in patients with idiopathic autonomic failure syndromes. Muscle Nerve 1996; 19(6): 758–63PubMedCrossRef
73.
Schwarz J, Kornhuber M, Bischoff C, et al. Electromyography of the external anal sphincter in patients with Parkinson’s disease and multiple system atrophy: frequency of abnormal spontaneous activity and polyphasic motor unit potentials. Muscle Nerve 1997; 20(9): 1167–72PubMedCrossRef
74.
Palace J, Chandiramani VA, Fowler CJ. Value of sphincter electromyography in the diagnosis of multiple system atrophy. Muscle Nerve 1997; 20(11): 1396–403PubMedCrossRef
75.
Tison F, Arne P, Sourgen C, et al. The value of external anal sphincter electromyography for the diagnosis of multiple system atrophy. Mov Disord 2000 Nov; 15(6): 1148–57PubMedCrossRef
76.
Valldeoriola F, Valls-Sole J, Tolosa ES, et al. Striatal and sphincter denervation in patients with progressive supranuclear palsy. Mov Disord 1995; 10: 550–5PubMedCrossRef
77.
Libelius R, Johansson F. Quantitative electromyography of the external anal sphincter in Parkinson’s disease and multiple system atrophy. Muscle Nerve 2000; 23(8): 1250–6PubMedCrossRef
78.
Giladi N, Simon ES, Korczyn AD, et al. Anal sphincter EMG does not distinguish between multiple system atrophy and Parkinson’s disease. Muscle Nerve 2000; 23(5): 731–4PubMedCrossRef
79.
Jost WH, Schimrigk K. Urinary incontinence in patients with Parkinson syndrome. Wien Klin Wochenschr 1996; 108(10): 296–302PubMed
80.
Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. J Neurol Sci 1996 Dec; 144 (1–2): 218-9
81.
Braune S, Elam M, Baron R, et al. Assessment of blood pressure regulation: recommendations for the practice of clinical neurophysiology. Guidelines of the International Federation of Clinical Physiology. Electroencephalogr Clin Neurophysiol Suppl 1999; 52: 287–91PubMed
82.
Braune S, Auer A, Schulte-Mönting J, et al. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex in normal controls. Clin Auton Res 1996; 6: 3–15PubMedCrossRef
83.
Braune S, Schulte-Mönting J, Schwerbrock S, et al. Retest variation of cardiovascular parameters in autonomic testing. J Auton Nerv Sys 1996; 60: 103–7CrossRef
84.
Clarke CE, Ray PS, Speller JM. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from early or advanced idiopathic Parkinson’s disease. Lancet 1999; 353(9161): 1329–30PubMedCrossRef
85.
Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998; 155(1): 60–7PubMedCrossRef
86.
Polinsky RJ, Taylor IL, Chew P, et al. Pancreatic polypeptide responses to hypoglycemia in chronic autonomic failure. J Clin Endocrinol Metab 1982; 54(1): 48–52PubMedCrossRef
87.
Schwarz J, Weis S, Kraft E, et al. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 1996; 60: 98–101PubMedCrossRef
88.
Schrag A, Kingsley D, Phatouros C, et al. Clinical usefulness of magnetic resonance imaging in multiple system atrophy [abstract]. Mov Disord 1997; 12: 829
89.
Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsonian syndromes with routine MRI. Neurology 2000 Feb 8; 54(3): 697–702PubMedCrossRef
90.
Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson’s disease using proton magnetic resonance spectroscopy. Ann Neurol 1995; 37: 204–10PubMedCrossRef
91.
Davie CA, Barker GJ, Machado C, et al. Proton magnetic resonance spectroscopy in Steele-Richardson-Olszewski syndrome. Mov Disord 1997; 12: 767–71PubMedCrossRef
92.
Schulz JB, Klockgether T, Petersen D, et al. Multiple system atrophy: natural history. MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT. J Neurol Neurosurg Psychiatry 1994; 57(9): 1047–56PubMedCrossRef
93.
Klockgether T, Schroth G, Diener H-C, et al. Idiopathic cerebellar ataxia of late onset: natural history and MRI morphology. J Neurol Neurosurg Psychiatry 1990; 53: 297–305PubMedCrossRef
94.
Brooks DJ, Ibanez V, Sawle GV, et al. Differing patterns of striatal 18-F-Dopa uptake in Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1990; 28: 547–55PubMedCrossRef
95.
de Volder AG, Francart J, Laterre C, et al. Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration. Ann Neurol 1989; 26: 239–47PubMedCrossRef
96.
Eidelberg D, Takikawa S, Moeller JR, et al. Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease. Ann Neurol 1993; 33: 518–27PubMedCrossRef
97.
Perani D, Bressi S, Testa D, et al. Clinical/metabolic correlations in multiple system atrophy. Arch Neurol 1995; 52: 179–85PubMedCrossRef
98.
Gilman S, Koeppe RA, Junck L, et al. Patterns of cerebral glucose metabolism detected with positron emission tomography differ in multiple system atrophy and olivopontocerebellar atrophy. Ann Neurol 1994; 36: 166–75PubMedCrossRef
99.
Rinne JO, Burn DJ, Mathias CJ, et al. Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol 1995; 37: 568–73PubMedCrossRef
100.
Gilman S, Koeppe RA, Junck L, et al. Benzodiazepine receptor binding in cerebellar degenerations studied with positron emission tomography. Ann Neurol 1995; 38: 176–85PubMedCrossRef
101.
Bannister R, Ardill L, Fentem P. An assessment of various methods of treatment of idiopathic orthostatic hypotension. Q J Med 1969; 38(152): 377–95PubMed
102.
Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992; 232(2): 139–45PubMedCrossRef
103.
van Lieshout JJ, Ten Harkel AD, Wieling W. Fludrocortisone and sleeping in the head-up position limit the postural decrease in cardiac output in autonomic failure. Clin Auton Res 2000; 10(1): 35–42PubMedCrossRef
104.
Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993; 95(1): 38–48PubMedCrossRef
105.
Low PA, Gilden JL, Freeman R, et al. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997; 277(13): 1046–51PubMedCrossRef
106.
Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998; 51(1): 120–4PubMedCrossRef
107.
Mathias CJ, Senard JM, Braune S, et al. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-centre dose-ranging study in multiple system atrophy (MSA) and pure autonomic failure (PAF). Clin Auton Res. In press
108.
Armstrong E, Mathias CJ. The effects of the somatostatin analogue, octreotide, on postural hypotension, before and after food ingestion, in primary autonomic failure. Clin Auton Res 1991; 1(2): 135–40PubMedCrossRef
109.
Hoeldtke RD, Horvath GG, Bryner KD, et al. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab 1998; 83(2): 339–43PubMedCrossRef
110.
Winkler AS, Marsden J, Parton M, et al. Erythropoietin deficiency and anaemia in multiple system atrophy. Mov Disord 2001; 16(2): 233–9PubMedCrossRef
111.
Shannon J, Jordan J, Costa F, et al. The hypertension of autonomic failure and its treatment. Hypertension 1997; 30(5): 1062–7PubMedCrossRef
112.
Jordan J, Shannon JR, Pohar B, et al. Contrasting effects of vasodilators on blood pressure and sodium balance in the hypertension of autonomic failure. J Am Soc Nephrol 1999; 10(1): 35–42PubMed
113.
Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol 1997; 80(1): 100–4PubMedCrossRef
114.
Hussain IF, Brady CM, Swinn MJ, et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry 2001 Sep; 71(3): 371–4PubMedCrossRef
115.
Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990 Jul 7; 336(8706): 32–4PubMedCrossRef
116.
Bösch SM, Wenning GK, Ransmayr G, et al. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry. In press
117.
Colosimo C, Merello M, Pontieri FE. Amantadine in parkinsonian patients unresponsive to levodopa: a pilot study [letter]. J Neurol 1996; 243: 422–5PubMedCrossRef
118.
Lang AE, Lozano AM. Parkinson’s disease. Second of two parts. N Engl J Med 1998 Oct 15; 339(16): 1130–43PubMedCrossRef
119.
Wenning GK, Tison F, Scherfler C, et al. Towards neurotransplantation in multiple system atrophy: clinical rational, pathophysiological basis and preliminary experimental evidence. Cell Transplant 2000; 9(2): 279–88PubMed
120.
Wenning GK, Granata R, Laboyrie PM, et al. Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration. Mov Disord 1996; 11: 522–32PubMedCrossRef
121.
Puschban Z, Scherfler C, Granata R, et al. Autoradiographic study of striatal dopamine reuptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesencephalic, striatal or co-grafts. Neuroscience 2000; 95: 377–88PubMedCrossRef
Metadaten
Titel
Multiple System Atrophy
Pathophysiology and Management
verfasst von
Dr Gregor Karl Wenning
Stefan Braune
Publikationsdatum
01.11.2001
Verlag
Springer International Publishing
Erschienen in
CNS Drugs / Ausgabe 11/2001
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200115110-00003

Weitere Artikel der Ausgabe 11/2001

CNS Drugs 11/2001 Zur Ausgabe

Review Article

Histamine and Betahistine in the Treatment of Vertigo

Current Opinion

Autism and Measles-Mumps-Rubella Vaccination

Leading Article

Reducing Bleeding Complications After Thrombolytic Therapy for Stroke

Adis Drug Evaluation

Olanzapine

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise